High Growth Tech Stocks To Watch In December 2024

As Christmas approaches, the ASX200 has seen a modest rise of 0.25% to 8335 points, with sectors like Real Estate and Industrials showing strong performance, while Staples have lagged behind. In this context of mixed sector performances and stable economic indicators, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation potential and adaptability in a fluctuating market environment.

Top 10 High Growth Tech Companies In Australia

Name	Revenue Growth	Earnings Growth	Growth Rating
Clinuvel Pharmaceuticals	21.38%	26.16%	★★★★★☆
Pureprofile	14.31%	71.53%	★★★★★☆
Adherium	86.80%	73.66%	★★★★★★
Telix Pharmaceuticals	21.55%	38.32%	★★★★★★
ImExHS	20.47%	111.20%	★★★★★★
AVA Risk Group	25.54%	77.32%	★★★★★★
Pointerra	56.62%	126.45%	★★★★★★
Wrkr	37.21%	98.46%	★★★★★★
Opthea	52.71%	63.26%	★★★★★★
SiteMinder	18.83%	60.52%	★★★★★☆

Click here to see the full list of 59 stocks from our ASX High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Infomedia (ASX:IFM)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Infomedia Ltd is a technology company that develops and supplies electronic parts catalogues, service quoting software, and e-commerce solutions for the automotive industry worldwide, with a market cap of A$524.66 million.

Operations: The company generates revenue primarily through its publishing segment, specifically in periodicals, amounting to A$140.83 million.

Infomedia, a player in the Australian tech sector, has been actively pursuing growth through mergers and acquisitions, as highlighted by its CEO Jens Monsees' recent announcement of seeking value-adding opportunities. Despite experiencing a substantial one-off loss of A$8.6M last fiscal year, the company's earnings have surged by 32.4% over the past year, outpacing the software industry's growth of 6.8%. Looking ahead, Infomedia is positioned for robust earnings expansion with an expected annual growth rate of 21%, significantly above Australia's market average of 12.5%. The addition of Joe Powell to the board underscores a strategic push towards leveraging his digital and educational sector expertise to foster further innovation and market penetration. This strategic direction is supported by solid financial indicators; Infomedia not only enjoys positive free cash flow but also anticipates revenue growth at a rate faster than the overall Australian market (6.8% vs. 5.8%). With a forecasted high return on equity at 20.7% in three years' time, Infomedia is reinforcing its foundation for sustained profitability and shareholder value amidst competitive pressures and dynamic market conditions.

• Click here to discover the nuances of Infomedia with our detailed analytical health report.

• Review our historical performance report to gain insights into Infomedia's's past performance.

Pro Medicus (ASX:PME)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies healthcare imaging software and radiology information system (RIS) software and services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe with a market cap of A$26.88 billion.

Operations: Pro Medicus generates revenue primarily through the production of integrated software applications for the healthcare industry, amounting to A$161.50 million. The company's operations span Australia, North America, and Europe, focusing on healthcare imaging and radiology information systems.

Pro Medicus stands out in the Australian tech landscape, not just for its impressive earnings growth of 36.5% over the past year—surpassing the Healthcare Services industry average of 20.4%—but also for its strategic positioning at recent industry events such as the Bell Potter Healthcare Conference. With an anticipated revenue increase of 18.7% annually, Pro Medicus is outpacing the broader Australian market's growth rate of 5.8%. Moreover, its projected return on equity is a robust 48.8% in three years, reflecting a strong financial foundation and operational efficiency that could drive further expansion in high-stakes medical imaging technology sectors where innovation is critical to maintaining competitive advantage.

• Click to explore a detailed breakdown of our findings in Pro Medicus' health report.

• Assess Pro Medicus' past performance with our detailed historical performance reports.

SiteMinder (ASX:SDR)

Simply Wall St Growth Rating: ★★★★★☆

Overview: SiteMinder Limited provides online guest acquisition platforms and commerce solutions for accommodation providers globally, with a market capitalization of A$1.74 billion.

Operations: SiteMinder generates revenue primarily from its Software & Programming segment, which contributed A$190.84 million. The company's business focuses on developing and marketing online platforms for guest acquisition and commerce solutions tailored for accommodation providers in Australia and internationally.

SiteMinder, an Australian tech firm, is navigating a transformative phase with significant board changes and strategic shifts aimed at enhancing its market position. Despite not being profitable currently, the company's revenue is expected to grow by 18.8% annually, outpacing the general market's growth of 5.8%. This growth trajectory is supported by a robust increase in earnings projected at 60.5% annually over the next three years. Moreover, SiteMinder's commitment to innovation is evident from its substantial R&D expenses which are crucial for sustaining long-term competitiveness in the dynamic tech landscape. The upcoming Annual General Meeting could further influence its strategic direction and stakeholder confidence as it continues to evolve within the high-stakes domain of digital booking technology.

• Get an in-depth perspective on SiteMinder's performance by reading our health report here.

• Explore historical data to track SiteMinder's performance over time in our Past section.

Next Steps

• Click through to start exploring the rest of the 56 ASX High Growth Tech and AI Stocks now.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com